• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    12/1/22 4:33:06 PM ET
    $AKAN
    $ALLR
    $BBLG
    $COSM
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKAN alert in real time by email

    Gainers

    • SCWorx (NASDAQ:WORX) shares moved upwards by 15.2% to $0.53 during Thursday's after-market session. The company's market cap stands at $6.8 million.
    • Allarity Therapeutics (NASDAQ:ALLR) shares increased by 13.92% to $0.5. Today's trading volume for this security ended up closing at 70.5K shares, which is 69.0 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $5.1 million.
    • Protagenic Therapeutics (NASDAQ:PTIX) stock increased by 12.06% to $0.6. The company's market cap stands at $10.3 million.
    • Akanda (NASDAQ:AKAN) stock moved upwards by 10.27% to $0.23. Trading volume for this security closed at 66.0K, accounting for 9.4% of its average full-day volume over the last 100 days. The company's market cap stands at $7.9 million.
    • Alaunos Therapeutics (NASDAQ:TCRT) shares rose 8.37% to $0.69. Alaunos Therapeutics's trading volume hit 78.5K shares by close, accounting for 2.2% of its average volume over the last 100 days. The company's market cap stands at $149.1 million.
    • Cosmos Holdings (NASDAQ:COSM) stock rose 6.83% to $0.42. At the close, Cosmos Holdings's trading volume reached 16.0 million shares. This is 40.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $35.6 million.

    Losers

    • Redhill Biopharma (NASDAQ:RDHL) stock decreased by 28.8% to $0.26 during Thursday's after-market session. This security traded at a volume of 483.4K shares come close, making up 16.5% of its average volume over the last 100 days. The company's market cap stands at $16.5 million. As per the press release, Q3 earnings came out 2 days ago.
    • Bone Biologics (NASDAQ:BBLG) shares decreased by 8.97% to $0.26. The market value of their outstanding shares is at $3.9 million.
    • Titan Pharmaceuticals (NASDAQ:TTNP) shares declined by 7.61% to $0.84. The company's market cap stands at $12.2 million.
    • Veeva Sys (NYSE:VEEV) shares declined by 7.54% to $177.0. The company's market cap stands at $27.4 billion. The company's, Q3 earnings came out today.
    • Sio Gene Therapies (NASDAQ:SIOX) shares decreased by 4.99% to $0.3. The market value of their outstanding shares is at $22.2 million.
    • Virax Biolabs Group (NASDAQ:VRAX) stock fell 4.97% to $1.53. At the close, Virax Biolabs Group's trading volume reached 72.7K shares. This is 2.7% of its average volume over the last 100 days. The company's market cap stands at $19.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKAN
    $ALLR
    $BBLG
    $COSM

    CompanyDatePrice TargetRatingAnalyst
    Veeva Systems Inc.
    $VEEV
    2/17/2026$205.00Underweight → Equal-Weight
    Morgan Stanley
    Veeva Systems Inc.
    $VEEV
    1/13/2026$215.00Sell
    Goldman
    Veeva Systems Inc.
    $VEEV
    1/8/2026Hold → Buy
    Truist
    Veeva Systems Inc.
    $VEEV
    12/12/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    Veeva Systems Inc.
    $VEEV
    11/13/2025$300.00Market Perform
    BMO Capital Markets
    Veeva Systems Inc.
    $VEEV
    10/7/2025$380.00Hold → Buy
    TD Cowen
    Veeva Systems Inc.
    $VEEV
    9/8/2025$330.00Neutral → Overweight
    Analyst
    Allarity Therapeutics Inc.
    $ALLR
    7/28/2025$9.00Buy
    Ascendiant Capital Markets
    More analyst ratings

    $AKAN
    $ALLR
    $BBLG
    $COSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Veeva Systems upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Veeva Systems from Underweight to Equal-Weight and set a new price target of $205.00

    2/17/26 8:05:30 AM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    Goldman resumed coverage on Veeva Systems with a new price target

    Goldman resumed coverage of Veeva Systems with a rating of Sell and set a new price target of $215.00

    1/13/26 9:18:31 AM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    Veeva Systems upgraded by Truist

    Truist upgraded Veeva Systems from Hold to Buy

    1/8/26 9:27:19 AM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    $AKAN
    $ALLR
    $BBLG
    $COSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/13/26 10:05:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/12/26 2:20:08 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/26/26 11:48:12 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $AKAN
    $ALLR
    $BBLG
    $COSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Haight Nelson M

    3 - Virax Biolabs Group Ltd (0001885827) (Issuer)

    3/31/26 3:15:09 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 3 filed by new insider Mccracken Nigel William

    3 - Virax Biolabs Group Ltd (0001885827) (Issuer)

    3/20/26 10:43:07 AM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 3 filed by new insider Tsimchi Ofer

    3 - RedHill Biopharma Ltd. (0001553846) (Issuer)

    3/19/26 7:35:14 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $ALLR
    $BBLG
    $COSM
    SEC Filings

    View All

    Allarity Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

    4/1/26 8:54:39 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-K filed by Cosmos Health Inc.

    NT 10-K - Cosmos Health Inc. (0001474167) (Filer)

    4/1/26 7:29:43 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SEC Form 10-K filed by Alaunos Therapeutics Inc.

    10-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)

    3/31/26 4:33:22 PM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $ALLR
    $BBLG
    $COSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

         Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for stenoparib, enabling accelerated development in advanced ovarian cancerDurable clinical benefit observed in ongoing stenoparib ovarian cancer study, including patients treated for nearly 30 months, with new Phase 2 protocol implementedExpansion of stenoparib development beyond ovarian cancer with the launch of a VA-funded Phase 2 combination study in recurrent small cell lung cancer TARPON SPRINGS, Fla., March 31, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2

    3/31/26 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation

    LONDON, March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system. The certifications were issued by LRQA, with an issue date of 18 February 2026 and an expiry date of 17 February 2029. Highlights:Virax believes the strengthened quality framework supports its post-acute infection syndromes ("PAIS") strategy by strengthening readiness for regulated in vitro diagnostic (

    3/31/26 7:34:00 AM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Akanda Corp. Driving Recurring Revenue Growth: $2 Million Cash Flow Secured Through Fiber Acquisition

    Toronto, Ontario--(Newsfile Corp. - March 26, 2026) - Akanda Corp. (NASDAQ:AKAN) ("Akanda") and its wholly owned subsidiary, First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications infrastructure developer in Mexico, are pleased to announce an expansion of its dark fiber network with the addition of approximately 200 kilometres, increasing total network coverage to approximately 900 kilometres across Central Mexico.This milestone is expected to materially advance FTF's strategy to build a scaled, high-margin, cash-flow-generating digital infrastructure platform in what the Company believes is one of Latin America's most attractive and undersupplied connectivity ma

    3/26/26 8:30:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    $ALLR
    $BBLG
    $COSM
    Leadership Updates

    Live Leadership Updates

    View All

    Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions

    Continues to deliver record revenue and improving operating metricsSignificant expansion in the United States underway, with NOOR and other Sky Premium Life products expected to drive strong profitability supported by gross margins of approximately 75%NOOR Collagen alone is projected to generate more than $12 million in annualized revenue Strong growth expected ahead, driven by organic progress and M&A pipeline including a recent LOI to acquire an $11.5 million pharmacy distribution network Holds valuable non-core strategic real estate and digital assets with an estimated fair market value exceeding $18 million, providing meaningful balance sheet flexibilityEvaluating potential monetization

    3/19/26 12:45:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

    CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

    2/24/26 12:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SCWorx Corp. Appoints New Chief Technology Officer to Accelerate Innovation in Healthcare Data Solutions

    Tampa, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SCWorx Corp. (NASDAQ:WORX), a leading provider of data management and software solutions for the healthcare industry, today announced the appointment of Anders Ohlsson, a seasoned technology executive, as its new Chief Technology Officer (CTO). This strategic hire underscores SCWorx's commitment to advancing its data platform and expanding its suite of data management and software solutions for healthcare providers. Mr. Ohlsson has over 25 years of experience in software engineering, cloud infrastructure, and machine learning applications. Prior to joining SCWorx, he held senior leadership roles at WideOrbit, where he spearheaded the developm

    9/3/25 11:44:49 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AKAN
    $ALLR
    $BBLG
    $COSM
    Financials

    Live finance-specific insights

    View All

    Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

         Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for stenoparib, enabling accelerated development in advanced ovarian cancerDurable clinical benefit observed in ongoing stenoparib ovarian cancer study, including patients treated for nearly 30 months, with new Phase 2 protocol implementedExpansion of stenoparib development beyond ovarian cancer with the launch of a VA-funded Phase 2 combination study in recurrent small cell lung cancer TARPON SPRINGS, Fla., March 31, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2

    3/31/26 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veeva Acquires Ostro, the Leading Brand Engagement Platform for Life Sciences

    PLEASANTON, Calif., March 10, 2026 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced the acquisition of Ostro, the leading brand engagement platform for life sciences that gives patients and doctors immediate, compliant answers through an easy-to-use AI-driven chat experience. Ostro-powered brand websites allow customers to easily ask questions and receive approved information, resources, and next steps in real-time. Leveraging this rich engagement data, Ostro also generates deep insights brands use to improve reach and engagement.Ostro utilizes a combination of conversa

    3/10/26 11:45:00 AM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    Veeva Announces Fourth Quarter and Fiscal Year 2026 Results

    Fiscal Year 2026 Total Revenues of $3,195.3M, up 16% Year Over YearQ4 Total Revenues of $836.0M, up 16% Year Over YearFiscal Year 2026 Subscription Revenues of $2,684.2M, up 17% Year Over YearQ4 Subscription Revenues of $707.7M, up 16% Year Over YearPLEASANTON, Calif., March 4, 2026 /PRNewswire/ -- Veeva Systems Inc. (NYSE:VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its fourth quarter and fiscal year ended January 31, 2026. "The agentic transformation underway represents a substantial opportunity for Ve

    3/4/26 4:05:00 PM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    $AKAN
    $ALLR
    $BBLG
    $COSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    11/26/24 5:02:01 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

    11/14/24 7:19:34 PM ET
    $BBLG
    Industrial Specialties
    Health Care